drugset / Trial / NCT02719028

Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia

NCT02719028 ↗

Phase 2 Completed 120 enrolled Golden Biotechnology Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

Identified the efficacy of Antroquinonol (Hocena 50mg) in triglyceride, lipid-lowering and fatty liver.

Timeline

Start
2016-05
Primary completion
2018-09-27
Completion
2019-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Antroquinonol Small molecule 50 mg Oral
Subject Antroquinonol Small molecule 100 mg Oral
Subject Antroquinonol Small molecule 150 mg Oral

Indications